Neurocrine Biosciences (NBIX) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• Neurocrine Biosciences is scheduled to report Q1 2026 results after the market close on Tuesday, May 5, 2026, with analysts expecting $1.15 EPS and $770.0 million in revenue (conference call at 4:30 PM ET).
• In the prior quarter the company reported $1.88 EPS, missing consensus of $2.36 while generating $805.5 million in revenue, and analysts now forecast about $6 EPS for both the current and next fiscal years.
• The stock trades near $128 with a market cap of about $12.9 billion and a P/E of 27.48; MarketBeat shows a consensus rating of Moderate Buy and a consensus target price of $180.45, with ~92.6% institutional ownership.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) is expected to issue its Q1 2026 results after the market closes on Tuesday, May 5th. Analysts expect the company to announce earnings of $1.15 per share and revenue of $770.00 million for the quarter. Parties can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 4:30 PM ET.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its quarterly earnings data on Wednesday, February 11th. The company reported $1.88 earnings per share for the quarter, missing analysts' consensus estimates of $2.36 by ($0.48). The firm had revenue of $805.50 million for the quarter, compared to analysts' expectations of $804.21 million. Neurocrine Biosciences had a net margin of 16.73% and a return on equity of 16.48%. The business's quarterly revenue was up 28.3% on a year-over-year basis. During the same period in the prior year, the business posted $1.69 earnings per share. On average, analysts expect Neurocrine Biosciences to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Neurocrine Biosciences Trading Up 0.3%

Shares of NASDAQ NBIX opened at $128.04 on Tuesday. The stock's 50-day moving average is $130.15 and its 200 day moving average is $137.88. The stock has a market cap of $12.88 billion, a price-to-earnings ratio of 27.48, a P/E/G ratio of 0.67 and a beta of 0.35. Neurocrine Biosciences has a 1-year low of $104.73 and a 1-year high of $160.18.

Institutional Investors Weigh In On Neurocrine Biosciences

A number of large investors have recently made changes to their positions in the business. AQR Capital Management LLC grew its position in shares of Neurocrine Biosciences by 18.0% in the 4th quarter. AQR Capital Management LLC now owns 3,271,706 shares of the company's stock worth $462,652,000 after buying an additional 498,058 shares during the last quarter. Northern Trust Corp grew its position in shares of Neurocrine Biosciences by 31.9% in the 4th quarter. Northern Trust Corp now owns 1,221,184 shares of the company's stock worth $173,201,000 after buying an additional 295,470 shares during the last quarter. Deerfield Management Company L.P. grew its position in shares of Neurocrine Biosciences by 1.4% in the 3rd quarter. Deerfield Management Company L.P. now owns 1,184,345 shares of the company's stock worth $166,258,000 after buying an additional 16,543 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Neurocrine Biosciences by 2.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 850,632 shares of the company's stock worth $120,645,000 after buying an additional 21,085 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of Neurocrine Biosciences by 0.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 716,475 shares of the company's stock worth $101,612,000 after buying an additional 6,353 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

NBIX has been the topic of a number of analyst reports. Truist Financial decreased their price target on Neurocrine Biosciences from $169.00 to $140.00 and set a "buy" rating on the stock in a research note on Tuesday, February 17th. Wedbush lifted their price target on Neurocrine Biosciences from $151.00 to $166.00 and gave the stock an "outperform" rating in a research note on Tuesday, April 7th. Wells Fargo & Company decreased their price target on Neurocrine Biosciences from $180.00 to $175.00 and set an "overweight" rating on the stock in a research note on Friday, February 13th. JPMorgan Chase & Co. lifted their price target on Neurocrine Biosciences from $176.00 to $177.00 and gave the stock an "overweight" rating in a research note on Thursday, March 12th. Finally, Leerink Partners lifted their price target on Neurocrine Biosciences from $160.00 to $170.00 and gave the stock an "outperform" rating in a research note on Wednesday, April 22nd. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $180.45.

About Neurocrine Biosciences

Neurocrine Biosciences NASDAQ: NBIX is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine's operations encompass drug discovery, clinical development and commercialization activities.

The company's lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.